Published in Nat Commun on September 21, 2016
Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy. Exp Mol Med (2017) 0.75
Targeting of IL-2 to cytotoxic lymphocytes as an improved method of cytokine-driven immunotherapy. Oncoimmunology (2017) 0.75
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology (2017) 0.75
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol (2003) 6.95
Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science (2006) 6.38
Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc Natl Acad Sci U S A (2002) 5.17
Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg (1989) 3.58
LacZ inducible, antigen/MHC-specific T cell hybrids. Int Immunol (1994) 3.47
Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Science (2015) 3.35
Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet (2000) 3.13
Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol (2013) 2.98
CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol (2006) 2.10
Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature (2012) 2.08
Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors. Chem Biol (2011) 2.05
IL-2: the first effective immunotherapy for human cancer. J Immunol (2014) 1.71
UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J Immunol (2002) 1.61
Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms. Immunity (2015) 1.57
Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci U S A (2010) 1.53
Endocytosis of interleukin 2 receptors in human T lymphocytes: distinct intracellular localization and fate of the receptor alpha, beta, and gamma chains. J Cell Biol (1995) 1.52
IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25. Proc Natl Acad Sci U S A (2010) 1.50
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer (2013) 1.48
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. J Immunother (2013) 1.48
Zoonotic orthopoxviruses encode a high-affinity antagonist of NKG2D. J Exp Med (2007) 1.34
Perforin: structure, function, and role in human immunopathology. Immunol Rev (2010) 1.30
Vav1 controls DAP10-mediated natural cytotoxicity by regulating actin and microtubule dynamics. J Immunol (2006) 1.30
Costimulation of multiple NK cell activation receptors by NKG2D. J Immunol (2002) 1.27
DAP12 signaling directly augments proproliferative cytokine stimulation of NK cells during viral infections. J Immunol (2006) 1.26
Murine Nkg2d and Cd94 are clustered within the natural killer complex and are expressed independently in natural killer cells. Proc Natl Acad Sci U S A (1998) 1.18
Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma. Ann Oncol (2007) 1.14
IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J Clin Invest (2014) 1.12
New prospects on the NKG2D/NKG2DL system for oncology. Oncoimmunology (2013) 1.10
Strain-specific variation in murine natural killer gene complex contributes to differences in immunosurveillance for urethane-induced lung cancer. Cancer Res (2012) 0.92
The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma. Expert Opin Investig Drugs (2009) 0.92
Selectively expanding subsets of T cells in mice by injection of interleukin-2/antibody complexes: implications for transplantation tolerance. Transplant Proc (2012) 0.91
Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution. Proc Natl Acad Sci U S A (2015) 0.91
Crystal structure of the cowpox virus-encoded NKG2D ligand OMCP. J Virol (2012) 0.89
Cancer immunoediting of the NK group 2D ligand H60a. J Immunol (2011) 0.89
Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer. Clin Cancer Res (2007) 0.88
Human IL-2 mutein with higher antitumor efficacy than wild type IL-2. J Immunol (2013) 0.87
Susceptibility of various strains of mice to urethan-induced lung tumors and depressed natural killer cell activity. J Natl Cancer Inst (1981) 0.82
Distinct clinical and laboratory activity of two recombinant interleukin-2 preparations. Clin Cancer Res (1999) 0.82
Efficient internalization of IL-2 depends on the distal portion of the cytoplasmic tail of the IL-2R common gamma-chain and a lymphoid cell environment. J Immunol (2000) 0.82
Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. Immunity (2015) 0.81
Chimera of IL-2 linked to light chain of anti-IL-2 mAb mimics IL-2/anti-IL-2 mAb complexes both structurally and functionally. ACS Chem Biol (2013) 0.81
Antibody-based delivery of IL2 and cytotoxics eradicates tumors in immunocompetent mice. Mol Cancer Ther (2014) 0.80
Influence of natural killer cells and perforin‑mediated cytolysis on the development of chemically induced lung cancer in A/J mice. Cancer Immunol Immunother (2014) 0.80
Unique pulmonary antigen presentation may call for an alternative approach toward lung cancer immunotherapy. Oncoimmunology (2013) 0.78
Characterization of lymphokine-activated killing by human peripheral blood mononuclear cells stimulated with interleukin 2 (IL-2) analogs specific for the intermediate affinity IL-2 receptor. Cell Immunol (1993) 0.76
Release of Soluble Ligands for the Activating NKG2D Receptor: One More Immune Evasion Strategy Evolved by HIV-1 ? Curr Drug Targets (2015) 0.76